Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3944409
Max Phase: Preclinical
Molecular Formula: C48H54ClN7O6S
Molecular Weight: 892.52
Molecule Type: Small molecule
Associated Items:
ID: ALA3944409
Max Phase: Preclinical
Molecular Formula: C48H54ClN7O6S
Molecular Weight: 892.52
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN1[C@@H]2CC[C@H]1CC(Nc1ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3ccc4[nH]ccc4c3)cc1[N+](=O)[O-])C2
Standard InChI: InChI=1S/C48H54ClN7O6S/c1-48(2)18-16-33(42(29-48)31-4-6-34(49)7-5-31)30-54-20-22-55(23-21-54)38-10-13-41(46(27-38)62-39-11-14-43-32(24-39)17-19-50-43)47(57)52-63(60,61)40-12-15-44(45(28-40)56(58)59)51-35-25-36-8-9-37(26-35)53(36)3/h4-7,10-15,17,19,24,27-28,35-37,50-51H,8-9,16,18,20-23,25-26,29-30H2,1-3H3,(H,52,57)/t35?,36-,37+
Standard InChI Key: NFCFIIICOCRIAE-SCGMLGLWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 892.52 | Molecular Weight (Monoisotopic): 891.3545 | AlogP: 9.46 | #Rotatable Bonds: 12 |
Polar Surface Area: 153.15 | Molecular Species: ZWITTERION | HBA: 10 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.15 | CX Basic pKa: 9.22 | CX LogP: 7.91 | CX LogD: 7.11 |
Aromatic Rings: 5 | Heavy Atoms: 63 | QED Weighted: 0.08 | Np Likeness Score: -0.86 |
1. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
Source(1):